Cardiovascular Disease in Pregnancy: Contemporary Cardio-Obstetric Assessment and Management

Pregnancy can reveal previously unrecognized cardiovascular disease and complicate the management of established cardiac conditions. Assessment must account for maternal health, fetal well-being, gestational age and the changing demands of pregnancy and the postpartum period.

Contemporary cardio-obstetric care connects risk assessment, appropriate investigations, individualized treatment and coordinated follow-up. This overview highlights practical principles from European guidance and complementary cardiovascular and obstetric recommendations.

Preconception Assessment and the Pregnancy Heart Team

Women with established cardiovascular disease benefit from assessment before conception to review their diagnosis, functional status, treatment and reproductive goals.

The 2025 ESC guideline uses the modified World Health Organization classification, mWHO 2.0, to guide maternal cardiovascular risk assessment. Women classified as mWHO II–III or higher should receive Pregnancy Heart Team care from preconception through the postpartum period.

ESC 2025 guideline and published correction: [1] [2]

The highest-risk category, mWHO IV, requires explicit counselling about the exceptionally high maternal and fetal risks. Shared decision-making should include discussion of all relevant options, psychological support and respect for the woman’s autonomy.

Clinical Assessment of Palpitations and Arrhythmias

Palpitations are common during pregnancy, but symptoms should be assessed in context. Initial evaluation includes a detailed history, examination, blood pressure measurement and a resting 12-lead ECG.

The clinical question is whether symptoms reflect benign ectopy or an arrhythmia requiring further investigation and treatment. Associated syncope, underlying cardiac disease and abnormal examination or ECG findings increase concern.

Management should involve discussion of both treatment-related risks and the risks of leaving a significant arrhythmia untreated.

Cardiovascular Imaging

Ultrasound-based assessment is particularly useful during pregnancy because it avoids ionizing radiation. Echocardiography can provide information about ventricular function, valve disease and cardiac structure.

MRI can answer selected additional questions when clinically indicated. Gadolinium should be restricted to situations where its diagnostic contribution is expected to improve maternal or fetal outcomes.

Pregnancy should not prevent a necessary diagnostic investigation. When radiography, CT or nuclear imaging is required to answer an important clinical question, it should not automatically be withheld. The investigation should be selected according to its clinical benefit and the available alternatives.

Hypertension and Pre-eclampsia Risk

For chronic hypertension during pregnancy, the 2025 AHA/ACC guideline recommends antihypertensive treatment to achieve blood pressure below 140/90 mmHg. Labetalol and extended-release nifedipine are preferred agents.

Severe hypertension—systolic pressure of at least 160 mmHg or diastolic pressure of at least 110 mmHg, confirmed promptly—requires urgent treatment. This is not a situation for routine outpatient adjustment.

Women with hypertension should also receive counselling about low-dose aspirin to reduce pre-eclampsia risk. Eligibility, initiation and dosing should follow the obstetric care plan and applicable local guidance.

ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors should not be used during pregnancy. Atenolol should also be avoided. Medication review is therefore essential before conception or as soon as pregnancy is recognized.

Treatment of Significant Arrhythmias

Electrical cardioversion can be performed during pregnancy when indicated; maternal instability should not be allowed to persist because of pregnancy.

For a regular narrow-complex supraventricular tachycardia in a hemodynamically stable patient, vagal manoeuvres are usually the initial approach, followed by intravenous adenosine when needed in a monitored clinical setting. Hemodynamic instability requires prompt synchronized cardioversion.

Pre-excited atrial fibrillation is a different emergency: AV nodal blockers should be avoided because they may accelerate conduction through an accessory pathway. Urgent specialist management is required. [5] [6]

For atrial fibrillation, treatment depends on hemodynamic status, structural heart disease and the need for rate or rhythm control. Metoprolol, propranolol and digoxin are established options for selected patients requiring rate control.

Flecainide or sotalol may be appropriate for rhythm maintenance in selected women without structural heart disease. These are specialist decisions requiring consideration of contraindications, monitoring and the specific arrhythmia.

Beta-blockers therefore have an important place in pregnancy-related cardiovascular care, but the appropriate agent and indication must be identified rather than treating all drugs in the class as interchangeable.

When beta-blockers are indicated, the agent should be selected for the maternal condition. Fetal growth surveillance and awareness of possible neonatal bradycardia or hypoglycemia are important. Treatment should not be stopped abruptly without clinical advice.

Atenolol should be avoided during pregnancy. Safety during pregnancy and safety during breastfeeding require separate, agent-specific assessments. [1] [7]

Anticoagulation Requires an Indication-Specific Plan

Anticoagulation decisions differ between venous thromboembolism, atrial fibrillation and mechanical heart valves. Low-molecular-weight heparin is generally preferred for acute VTE during pregnancy, but this should not be extrapolated to a universal regimen for mechanical valves.

Mechanical heart valves require a specialist plan balancing maternal valve thrombosis against fetal risks. The regimen may change during pregnancy and around delivery. When LMWH is used for a mechanical valve, specialist dose adjustment and anti-Xa monitoring are essential.

Direct oral anticoagulants are not recommended during pregnancy. Postpartum treatment must account for bleeding risk, the anticoagulation indication and breastfeeding. Heparins and warfarin are established options during lactation when indicated.

Patients should never stop or switch anticoagulation independently, particularly when a mechanical valve is present. [1] [8]

Heart Failure and Peripartum Cardiomyopathy

Peripartum cardiomyopathy is a diagnosis of exclusion involving new heart failure with left ventricular systolic dysfunction, typically an ejection fraction below 45%, arising toward the end of pregnancy or after delivery.

Assessment should consider alternative explanations, including pre-existing cardiomyopathy and significant valve disease.

Treatment differs between pregnancy and the postpartum period. During pregnancy, selected beta-blockers, hydralazine with nitrates, and diuretics for congestion may be used under specialist supervision. Postpartum treatment should be reassessed alongside breastfeeding considerations.

Standard heart-failure treatment outside pregnancy cannot be transferred unchanged into pregnancy. ACE inhibitors, ARBs, ARNIs and SGLT2 inhibitors should not be used during pregnancy. Postpartum therapy requires a separate review of maternal indications and lactation compatibility. [1] [10]

Anticoagulation may be appropriate when thromboembolic risk is elevated, including marked ventricular dysfunction or atrial fibrillation. It is not an automatic requirement for every patient.

Recovery of ventricular function does not remove the need for follow-up or specialist counselling before another pregnancy.

Valve Disease, Aortopathy and Other Established Conditions

Risk assessment must reflect the specific lesion and its severity. Significant valve disease, aortic disease, pulmonary hypertension, congenital heart disease and cardiomyopathy require condition-specific planning.

Medication and anticoagulation decisions should be individualized by the relevant specialist team. Generic advice cannot replace an assessment of the underlying condition.

Delivery Planning

A written delivery plan should be agreed in advance and include the cardiovascular, obstetric and anesthetic teams.

Vaginal delivery is preferred for most women with cardiovascular disease. The underlying condition and clinical status determine when an alternative approach is needed.

Postpartum Care: An Essential Part of Treatment

Cardiovascular care should continue after delivery. The 2026 ACC Expert Consensus Decision Pathway identifies the early postpartum period, especially the first two weeks, as a time of particular vulnerability.

Planning should begin before discharge and include symptom education, blood pressure management when relevant, medication review and clear follow-up arrangements.

Postpartum cardiovascular care should begin before discharge, include early follow-up tailored to risk, and continue through the first year with transition to long-term preventive care. The first two weeks are particularly vulnerable, but cardiovascular risk does not end after this period. [11] [12]

New or worsening cardiovascular symptoms require prompt assessment rather than automatic attribution to normal recovery.

When to Seek Urgent Medical Assessment

Seek urgent medical assessment for new chest pain, severe or sudden breathlessness, fainting, coughing blood, new neurological symptoms, or a severe persistent headache with visual disturbance. During pregnancy, systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg requires urgent assessment. Do not wait for a routine appointment or repeatedly check BP at home when severe symptoms are present. In Qatar, call 999 for a medical emergency.

A normal blood pressure reading does not exclude a cardiovascular or obstetric emergency. [1] [3]

Comprehensive care also considers breastfeeding, mental health, contraception and access to continuing care.

Long-Term Cardiovascular Prevention

Adverse pregnancy outcomes, including hypertensive disorders, gestational diabetes and preterm birth, can identify women at increased future cardiovascular risk.

The postpartum period provides an opportunity to review cardiometabolic risk factors and establish preventive care. Follow-up should connect obstetric and cardiovascular services with primary care, extending beyond the initial postpartum visit.

The goal is to support maternal cardiovascular health throughout recovery and into subsequent years.